`BIB_359`

Replimune RP1 (vusolimogene oderparepvec) — FDA double-rejection in advanced melanoma; April 2026.

Evidence grade: A
Tier: 1 (Replimune official + Cancer Letter + Scientific American)
Cited by tasks: 17, 18, 19a
Identifiers: —

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_359/findings.md (research corpus). This page is a short context summary — not individualised medical advice.